Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238588 · ClinicalTrials.gov registry record · NA
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
A NA study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01238588 is a NA study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 24 participants.
The verdict
NCT01238588, a NA study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).
Interventions
- DRUG Sevelamer Carbonate (Renvela)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-06-10 |
| Est. Completion | 2016-04-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238588
The ClinicalTrials.gov registry entry for NCT01238588 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sevelamer Carbonate (Renvela) is the first listed.
NCT01238588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01238588 about?
NCT01238588 is a clinical study titled "The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan". The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).
What is the current status of trial NCT01238588?
This trial is currently terminated. It is a NA study. The enrollment target is 24 participants. The study started on 2011-06-10. Estimated completion is 2016-04-08.
What interventions are being tested in trial NCT01238588?
The interventions under investigation include: Sevelamer Carbonate (Renvela) (DRUG).
Who is sponsoring clinical trial NCT01238588?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.